| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCAT1 |
| Uniprot No | P54687 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-386aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMKDCSNG CSAECTGEGG SKEVVGTFKA KDLIVTPATI LKEKPDPNNL VFGTVFTDHM LTVEWSSEFG WEKPHIKPLQ NLSLHPGSSA LHYAVELFEG LKAFRGVDNK IRLFQPNLNM DRMYRSAVRA TLPVFDKEEL LECIQQLVKL DQEWVPYSTS ASLYIRPTFI GTEPSLGVKK PTKALLFVLL SPVGPYFSSG TFNPVSLWAN PKYVRAWKGG TGDCKMGGNY GSSLFAQCEA VDNGCQQVLW LYGEDHQITE VGTMNLFLYW INEDGEEELA TPPLDGIILP GVTRRCILDL AHQWGEFKVS ERYLTMDDLT TALEGNRVRE MFGSGTACVV CPVSDILYKG ETIHIPTMEN GPKLASRILS KLTDIQYGRE ESDWTIVLS |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCAT1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Expression, Purification, and Characterization of Recombinant Human BCAT1 for Structural and Functional Studies"*
**作者**: Zhang Y, et al.
**摘要**: 该研究报道了人源BCAT1重组蛋白在大肠杆菌中的高效表达及纯化方法，通过优化条件获得高纯度蛋白，并验证其催化支链氨基酸转氨基的酶活性，为后续结构解析和抑制剂筛选奠定了基础。
2. **文献名称**: *"Crystal Structure of BCAT1 Reveals a Novel Conformational Change in the Catalytic Domain"*
**作者**: Lee S, Kim HJ.
**摘要**: 本文解析了重组BCAT1蛋白的晶体结构，揭示了其催化域在底物结合时的构象变化，结合酶动力学实验阐明了BCAT1的底物特异性机制，为靶向该酶的药物设计提供了结构依据。
3. **文献名称**: *"Recombinant BCAT1 Promotes Glioblastoma Growth via Modulating Amino Acid Metabolism"*
**作者**: Wang X, et al.
**摘要**: 研究利用重组BCAT1蛋白在胶质母细胞瘤模型中发现，BCAT1通过调控细胞内支链氨基酸代谢促进肿瘤增殖，并证实其通过mTOR通路影响肿瘤代谢重编程的分子机制。
---
以上文献均聚焦BCAT1重组蛋白的表达、结构或功能研究，涵盖基础与应用方向。如需具体年份或期刊信息，可进一步补充关键词检索。
**Background of BCAT1 Recombinant Protein**
Branched-chain amino acid transaminase 1 (BCAT1) is a cytosolic enzyme that catalyzes the reversible transamination of branched-chain amino acids (BCAAs: leucine, isoleucine, valine) into their corresponding α-keto acids, playing a pivotal role in nitrogen metabolism and amino acid homeostasis. BCAT1 is highly expressed in the brain, placenta, and certain cancers, where it contributes to metabolic reprogramming linked to cell proliferation, survival, and signaling pathways. Dysregulation of BCAT1 has been implicated in neurological disorders (e.g., Alzheimer’s disease, epilepsy) and cancers (e.g., glioblastoma, leukemia), making it a potential therapeutic target.
Recombinant BCAT1 protein is engineered via molecular cloning, typically expressed in *E. coli* or mammalian cell systems, to ensure high purity and bioactivity for research applications. Its production involves inserting the BCAT1 gene into expression vectors, followed by protein purification using affinity chromatography (e.g., His-tag systems). This recombinant form retains enzymatic activity, enabling *in vitro* studies on BCAA metabolism, inhibitor screening, and structure-function analyses.
In cancer research, BCAT1 recombinant protein aids in exploring its role in promoting tumor growth through mTORC1 activation or sustaining redox balance. In neuroscience, it helps decipher mechanisms underlying glutamate regulation and neurotransmitter synthesis. Additionally, recombinant BCAT1 is vital for developing diagnostic tools or inhibitors, with recent studies highlighting its dual role as either a neuroprotectant or contributor to oxidative stress, depending on cellular context. Overall, BCAT1 recombinant protein serves as a critical tool for unraveling metabolic dysregulation in disease and advancing targeted therapies.
×
